Aktuellt
SENASTE
Sprint Bioscience delivered Q3 sales within the recent range at SEK 14.8m, mostly related to the Day One Biopharmaceuticals partner and the VADA project. The cash balance was SEK 31.7m in Q3 (36m in Q2 2024). Sprint Bioscience continues to market and attracts interest from potential partners for TREX1 (DISA), NIMA and MASH programs, and during the quarter, Sprint Bioscience also completed the handover process for PETRA01. Our Base Case ahead of Q3 was SEK 3.00 (Bull SEK 12 and Bear SEK 0.50).
LÄS MER
